Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients

Background: Chronic Hepatitis-C virus [HCV] infection is endemic in Egypt, with the highest prevalence worldwide. There are few studies on the effectiveness and safety of direct acting antivirals in treating geriatric patients with chronic HCV. Aim of the work: This study aimed to determine the eff...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohamed G. Mohamed, Mohamed B. Bastawy, Mostafa A. Elhawary, Mohamed R. Rashed
Formato:	article
Lenguaje:	EN
Publicado:	Al-Azhar University, Faculty of Medicine (Damietta) 2021
Materias:	egyptians hepatitis-c virus sofosbuvir daclatasvir elderly Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/6200c19577674c1fbc192a343a18ef86
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6200c19577674c1fbc192a343a18ef86
record_format	dspace
spelling	oai:doaj.org-article:6200c19577674c1fbc192a343a18ef862021-12-02T14:10:53ZSafety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients2636-41742682-378010.21608/ijma.2020.46788.1195https://doaj.org/article/6200c19577674c1fbc192a343a18ef862021-01-01T00:00:00Zhttps://ijma.journals.ekb.eg/article_122310_7ed0de59fec0ff88adfd008752274fc2.pdfhttps://doaj.org/toc/2636-4174https://doaj.org/toc/2682-3780Background: Chronic Hepatitis-C virus [HCV] infection is endemic in Egypt, with the highest prevalence worldwide. There are few studies on the effectiveness and safety of direct acting antivirals in treating geriatric patients with chronic HCV. Aim of the work: This study aimed to determine the efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in treating chronic HCV infection in geriatric Egyptian patients. Patients and Methods: In this study, we analyzed the medical files of 100 patients with chronic HCV, ≥ 65 years old, naïve, and eligible for HCV treatment. Patients were classified into: Group I; 50 patients without cirrhosis and Group II; 50 patients with Cirrhosis. All patients were subjected to history taking, clinical and laboratory evaluation. Electrocardiogram [ECG] and echocardiography were also conducted. Polymerase chain reaction [PCR] for HCV- ribonucleic acid [RNA] was performed and compared between groups at baseline, at the end of treatment, and at 12 weeks later. All patients underwent an abdominal ultrasound and fibrosis-4 [FIB-4] score. Group I was treated with sofosbuvir 400 mg and daclatasvir 60 mg once daily for 12 weeks, while weight-based ribavirin was added in group II. Results: Overall, 95 patients achieved sustained virological response[SVR]-12, three had failed treatment, and two had relapse. There were no significant differences in treatment success between the groups after treatment completion [HCV RNA was below the detection limit in 49 patients in group I and 48 patients in group II] and 12 weeks later [HCV RNA was below the detection limit in 48 patients in group I and 47 patients in group II], with one patient in group I and two patients in group II had failed treatment. There was also a significant decrease in alanine transaminase [ALT] and aspartate transaminase [AST] in both groups after treatment completion. Some patient symptoms like easy fatigability and dyspepsia have been improved with no significant cardiac changes after therapy. Conclusions: Sofosbuvir and daclatasvir with or without ribavirin are safe and effective in treating elderly Egyptian patients with chronic HCV infection.Mohamed G. MohamedMohamed B. BastawyMostafa A. ElhawaryMohamed R. RashedAl-Azhar University, Faculty of Medicine (Damietta)articleegyptianshepatitis-c virussofosbuvirdaclatasvirelderlyMedicine (General)R5-920ENInternational Journal of Medical Arts, Vol 3, Iss 1, Pp 1053-1059 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	egyptians hepatitis-c virus sofosbuvir daclatasvir elderly Medicine (General) R5-920
spellingShingle	egyptians hepatitis-c virus sofosbuvir daclatasvir elderly Medicine (General) R5-920 Mohamed G. Mohamed Mohamed B. Bastawy Mostafa A. Elhawary Mohamed R. Rashed Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
description	Background: Chronic Hepatitis-C virus [HCV] infection is endemic in Egypt, with the highest prevalence worldwide. There are few studies on the effectiveness and safety of direct acting antivirals in treating geriatric patients with chronic HCV. Aim of the work: This study aimed to determine the efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in treating chronic HCV infection in geriatric Egyptian patients. Patients and Methods: In this study, we analyzed the medical files of 100 patients with chronic HCV, ≥ 65 years old, naïve, and eligible for HCV treatment. Patients were classified into: Group I; 50 patients without cirrhosis and Group II; 50 patients with Cirrhosis. All patients were subjected to history taking, clinical and laboratory evaluation. Electrocardiogram [ECG] and echocardiography were also conducted. Polymerase chain reaction [PCR] for HCV- ribonucleic acid [RNA] was performed and compared between groups at baseline, at the end of treatment, and at 12 weeks later. All patients underwent an abdominal ultrasound and fibrosis-4 [FIB-4] score. Group I was treated with sofosbuvir 400 mg and daclatasvir 60 mg once daily for 12 weeks, while weight-based ribavirin was added in group II. Results: Overall, 95 patients achieved sustained virological response[SVR]-12, three had failed treatment, and two had relapse. There were no significant differences in treatment success between the groups after treatment completion [HCV RNA was below the detection limit in 49 patients in group I and 48 patients in group II] and 12 weeks later [HCV RNA was below the detection limit in 48 patients in group I and 47 patients in group II], with one patient in group I and two patients in group II had failed treatment. There was also a significant decrease in alanine transaminase [ALT] and aspartate transaminase [AST] in both groups after treatment completion. Some patient symptoms like easy fatigability and dyspepsia have been improved with no significant cardiac changes after therapy. Conclusions: Sofosbuvir and daclatasvir with or without ribavirin are safe and effective in treating elderly Egyptian patients with chronic HCV infection.
format	article
author	Mohamed G. Mohamed Mohamed B. Bastawy Mostafa A. Elhawary Mohamed R. Rashed
author_facet	Mohamed G. Mohamed Mohamed B. Bastawy Mostafa A. Elhawary Mohamed R. Rashed
author_sort	Mohamed G. Mohamed
title	Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
title_short	Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
title_full	Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
title_fullStr	Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
title_full_unstemmed	Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
title_sort	safety and efficacy of sofosbuvir and daclatasvir in the treatment of chronic hcv infection in elderly egyptian patients
publisher	Al-Azhar University, Faculty of Medicine (Damietta)
publishDate	2021
url	https://doaj.org/article/6200c19577674c1fbc192a343a18ef86
work_keys_str_mv	AT mohamedgmohamed safetyandefficacyofsofosbuviranddaclatasvirinthetreatmentofchronichcvinfectioninelderlyegyptianpatients AT mohamedbbastawy safetyandefficacyofsofosbuviranddaclatasvirinthetreatmentofchronichcvinfectioninelderlyegyptianpatients AT mostafaaelhawary safetyandefficacyofsofosbuviranddaclatasvirinthetreatmentofchronichcvinfectioninelderlyegyptianpatients AT mohamedrrashed safetyandefficacyofsofosbuviranddaclatasvirinthetreatmentofchronichcvinfectioninelderlyegyptianpatients
_version_	1718391909320228864

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients

Ejemplares similares